梯瓦製藥 TEVA 深滬

等待開盤 03-26 09:30:00 美东时间

29.46

+0.320

+1.10%

華盛通

立即下載

最高30.42
今開29.35
成交量 817.06万股
最低 29.28
昨收 29.14
總市值 343.21亿
52周最高 37.345
市盈率 ^靜 24.11
換手率 0.70%
52周最低 12.465
委比 -53.85%
總股本 11.65亿
歷史最高 69.8535
量比 1.18
振幅 3.91%
歷史最低 6.07
每手 1
風險率 6.86%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

Insiders have been trading these 5 stocks: (($ENPH)), (($ASTS)), (($APP)), (($C...

03-21 21:00
Corcept rises after insider buy worth over $3M

Corcept Therapeutics (CORT) traded higher on Friday after the company’s board member Leonard Baker Jr. disclosed that he purchased shares of the Korlym maker in a transaction worth more than $3M earli...

03-20 23:00
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

03-19 20:30
华生制药：从仿制药到创新药的转型范式

（来源：中国医药报）转自：中国医药报 2007年，赵宇天退休，Paul M.Bisaro接任华生制药CEO。Paul M.Bisaro曾任巴尔制药CEO，是...

03-19 08:40
Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech reported Q4 2025 revenues of $173 million (13% YoY growth) and FY 2025 revenues of $593 million (21% YoY growth). Adjusted EBITDA for Q4 was $69 million, while FY 2025 reached $137 million (27% YoY growth). Key milestones include approvals for AVT05 and AVT03 biosimilars and new commercial partnerships with Sandoz. The company expects 2026 revenues between $650-700 million and Adjusted EBITDA of $180-220 million, driven by new product la...

03-18 22:15
期权扫描 | 获Bernstein上调目标价，台积电期权成交激增256%！英伟达获一Call单押注涨至190美元

获Bernstein上调目标价，台积电期权成交激增256%！黄仁勋豪言万亿美元营收，英伟达获一Call单押注涨至190美元>>

03-17 19:45
Generic drug suppliers could face pressure from Strait of Hormuz closure

With 90% of prescriptions in the US filled for generic drugs, there is growing concern that supplies of the medications could be in short supply due to the ongoing situation in the Strait of Hormuz, a...

03-17 00:56
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价

今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元

03-05 13:56
黑石集团向梯瓦制药注资4亿美元，用于开发炎症性肠病治疗药物。

黑石集团向梯瓦制药注资4亿美元，用于开发炎症性肠病治疗药物。

03-04 07:15
Teva Pharmaceutical Industries' Teva Pharmaceuticals And Funds Managed By Blackstone Life Sciences Reveal A $400M Strategic Funding Agreement Spread Across Four Years To Support The Continued Clinical Development Of Duvakitug

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences ("BXLS") today announced a $400 million strategic funding agreement spread

03-04 06:03

派息除權日	每股總股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名稱	梯瓦制药
行業分類	制药
業務描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦製藥 TEVA 深 滬

29.46

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

梯瓦製藥 TEVA 深滬